| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698887 | Clinical Oncology | 2013 | 10 Pages |
Abstract
The decrease in SREs over time may not only be a result of the development of new generation bone-targeted agents, but also due to better systemic management and awareness of events associated with bone metastases.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Poon, L. Zeng, L. Zhang, H. Lam, U. Emmenegger, E. Wong, G. Bedard, N. Lao, R. Chow, E. Chow,